PortaWBC™
The first
affordable
point-of-care
white blood
cell count test
There are approximately 1.5 million cancer patients receiving chemotherapy in the United States annually. Prior to each chemotherapy treatment, a patient's white blood cell (WBC) level is examined to ensure that their count is high enough to receive therapy. As many as 15% of the patients often develop a neutropenia condition - low WBC count - after receiving chemotherapy. Patients taking Neupogen® or Neulasta® for the treatment of neutropenia are recommended to test their count 2-3 times a week. The PortaWBC™ white blood cell count test is the first affordable WBC count test that patients can easily perform in the convenience of their home.
The key advantages of this unique, patented product include:
- In-House Convenience:
- Healthcare providers can have patients test themselves at home and phone in the results.
- Laboratory Accuracy:
- The PortaWBC™ white blood cell count test provides accuracy similar to that of a lab.
- Fast Results
- Typically, results in less than 5 minutes.
- Easy to use:
- Requires less than 1 minute of hands-on time.
- Low Cost:
- Far less expensive than the other conventional testing instruments available today.
- Additional Applications:
- Cardiac care & infection evaluation, CD4 monitoring, subclinical mastitis detection.